Drugs that contain Progesterone
1. Crinone patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5543150 | ALLERGAN | Method of progesterone delivery and affect thereof |
Sep, 2013
(10 years ago) | |
Market Authorisation Date: 31 July, 1997
Treatment: Vaginal administration of progesterone using specified formulation
Dosage: GEL;VAGINAL
CRINONE family patents
2. Endometrin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7393543 | FERRING | Vaginally administratable progesterone-containing tablets and method for preparing same |
Nov, 2019
(4 years ago) | |
| US7320800 | FERRING | Vaginally administrable progesterone-containing tablets and method for preparing same |
Nov, 2019
(4 years ago) | |
| US7300664 | FERRING | Vaginally administrable progesterone-containing tablets and method for preparing same |
Nov, 2019
(4 years ago) | |
Market Authorisation Date: 21 June, 2007
Treatment: Endometrin is a progesterone indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment pr...
Dosage: INSERT;VAGINAL
ENDOMETRIN family patents
3. Milprosa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537584 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(4 years from now) | |
| US10548904 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(4 years from now) | |
| US8580293 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2023 |
Market Authorisation Date: 29 April, 2020
Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women
Dosage: SYSTEM;VAGINAL
MILPROSA family patents